APGE PEER ANALYSIS

Apogee Therapeutics, Inc. Common Stock — metric-by-metric comparison with peers and the industry median

APGEApogee Therapeutics, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
APGEIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
APGE+199.9%CSL-48.2%TLX-29.5%MSB+27.6%
Year-to-Date (YTD)
APGE+76.1%CSL-28.5%TLX+50.7%MSB-24.3%

Key Metric Comparison

P/E

Lower is better
APGECSL29.44TLXMSBMedian 17.91

ROE

Higher is better
APGE-28.5%CSL7.7%TLX-1.8%MSB-11.3%Median -47.5%

Net Margin

Higher is better
APGECSL9.2%TLX-0.9%MSB-115.3%Median -125.7%

Revenue Growth

Higher is better
APGE-100.0%CSL4.8%TLX56.3%MSB410.4%Median 5.1%

All Metrics

Valuation
MetricAPGECSLTLXMSBInd. Median
P/E29.4417.91
P/B7.372.206.373.51
EV/EBITDA10.21120.1414.82
P/S2.623.2431.6110.89
Financial Health
MetricAPGECSLTLXMSBInd. Median
Current Ratio32.592.571.435.90
Debt/Equity0.6%67.4%112.3%10.9%
NetDebt/EBITDA3.862.2213.131.15
Profitability
MetricAPGECSLTLXMSBInd. Median
Net Margin9.2%-0.9%-115.3%-125.7%
ROE-28.5%7.7%-1.8%-11.3%-47.5%
ROA-27.4%3.8%-0.7%-8.6%-35.8%
EBITDA Margin32.8%3.0%-76.6%-105.8%
Growth + Dividend
MetricAPGECSLTLXMSBInd. Median
Rev. Growth-100.0%4.8%56.3%410.4%5.1%
NI Growth-39.4%12.1%
Div. Yield2.5%0.0%0.2%
Payout103.1%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on APGE

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.